FINWIRES · TerminalLIVE
FINWIRES

歐洲、中東和非洲地區石油市場最新動態:儘管美伊衝突不斷,油價仍小幅走低

By

-- 週二,由於美國軍方啟動「自由行動」以打破霍爾木茲海峽的封鎖,油價下跌。 穆爾班原油期貨近月合約下跌1.2%,至每桶106美元;布蘭特原油期貨下跌2%,至每桶112.06美元。 然而,分析人士指出,美伊軍隊之間的直接交火以及阿聯酋富查伊拉石油碼頭遭到無人機襲擊,打破了持續一個月的停火協議,並重新引發了人們對全球能源危機長期存在的擔憂,油價跌幅因此大幅收窄。 分析家指出,在美軍艦艇遭到攻擊的消息傳出後,石油市場仍處於高度戒備狀態。 這場衝突爆發之際,美國正發起一項行動,旨在營救目前被困在波斯灣的商船。 據報道,美國中央司令部證實兩艘美國商船已成功通過霍爾木茲海峽,但隨後美伊軍隊之間發生的直接交火危及了四周前達成的停火協議。 阿聯酋報告稱,自4月8日停火協議生效以來,首次成功攔截了伊朗的飛彈和無人機,地區局勢因此進一步惡化。 然而,一架伊朗無人機成功襲擊了富查伊拉港的一個石油碼頭,引發了該設施的大火。 創紀錄的每日1000萬桶的供應損失已經耗盡了全球庫存,專家警告稱,如果霍爾木茲海峽繼續受阻,這場能源危機可能會持續到2026年底甚至2027年。

Related Articles

Commodities

Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand

Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says

Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD